ARTERIAL VASCULAR ENGINEERING INC
S-8, 1998-12-02
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Previous: BIOFIELD CORP \DE\, 8-K, 1998-12-02
Next: ARTERIAL VASCULAR ENGINEERING INC, S-8, 1998-12-02





    As filed with the Securities and Exchange Commission on December 2, 1998
                                                     Registration No. 333-
- --------------------------------------------------------------------------------

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM S-8
                             REGISTRATION STATEMENT
                                      UNDER
                           THE SECURITIES ACT OF 1933


                       ARTERIAL VASCULAR ENGINEERING, INC.
             (Exact name of registrant as specified in its charter)

        Delaware                                         94-3144218
(State of Incorporation)                    (I.R.S. Employer Identification No.)


                                3576 Unocal Place
                          Santa Rosa, California 95403

                    (Address of principal executive offices)


                           1996 Equity Incentive Plan

                            (Full title of the plan)


                               Lawrence J. Fassler
                        Vice President of Legal Affairs,
                          General Counsel and Secretary
                       Arterial Vascular Engineering, Inc.
                                3576 Unocal Place
                          Santa Rosa, California 95403
                                 (707) 525-0111

            (Name, address, including zip code, and telephone number,
                   including area code, of agent for service)


<TABLE>
                                                   CALCULATION OF REGISTRATION FEE

<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------

========================== ====================== ========================== =========================== ===========================
                                                      Proposed Maximum            Proposed Maximum
 Title of Securities to        Amount to be       Offering Price Per Share    Aggregate Offering Price           Amount of
      be Registered             Registered                   (1)                        (1)                   Registration Fee
========================== ====================== ========================== =========================== ===========================
<S>                             <C>                       <C>                        <C>                         <C>
Stock Options and Common
Stock (par value $.001)         3,000,000                 $30.9375                   $92,812,500.00              $25,801.88
========================== ====================== ========================== =========================== ===========================

- ------------------------------------------------------------------------------------------------------------------------------------
<FN>
(1)  Estimated  solely  for  the  purpose  of  calculating  the  amount  of  the
     registration fee pursuant to Rule 457(c), based upon $30.9375,  the average
     of the high and the low prices of Registrant's Common Stock on November 25,
     1998, as reported on the Nasdaq National Market.
</FN>
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

         Approximate  date of  commencement  of proposed sale to the public:  As
soon as practicable after this Registration Statement becomes effective.


<PAGE>


                    INCORPORATION BY REFERENCE OF CONTENTS OF
          REGISTRATION STATEMENTS ON FORM S-8 NOS. 333-3254, 333-3468,
                            333-22089, and 333-39777

         The  contents of  Registration  Statements  on Form S-8 Nos.  333-3254,
333-3468, 333-22089 and 333-39777,  respectively,  filed with the Securities and
Exchange  Commission  on April 5, 1996,  April 11,  1996,  February 20, 1997 and
November 7, 1997,  respectively,  are incorporated by reference herein with such
modifications as are set forth below.

Item 5.  Interests of Named Experts and Counsel

         Lawrence J. Fassler,  Vice President of Legal Affairs,  General Counsel
and Secretary of the Company,  whose opinion is included  herewith as Exhibit 5,
holds 33,200 shares of common stock of the Company and holds options to purchase
an  additional  51,125  shares of common  stock of the Company as of December 2,
1998, none of which were exercisable as of such date.


                                    EXHIBITS


Exhibit
Number
- ------
5                 Opinion of Lawrence J. Fassler

23.1              Consent of Ernst & Young LLP, Independent Auditors

23.2              Consent of Lawrence J. Fassler (included in Exhibit 5)

24                Power of Attorney (contained on the signature page)



<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of the Securities Act of 1933, as amended,
the Company  certifies that it has  reasonable  grounds to believe that it meets
all of the  requirements  for  filing  on  Form  S-8 and has  duly  caused  this
Registration Statement to be signed on its behalf by the undersigned,  thereunto
duly authorized,  in the City of Santa Rosa, State of California, on December 2,
1998.


                                      ARTERIAL VASCULAR ENGINEERING, INC.


                                      By: /s/ Scott J. Solano
                                          --------------------------------------
                                          Scott J. Solano
                                          President and Chief Executive Officer


                                POWER OF ATTORNEY

         KNOW ALL PERSONS BY THESE  PRESENTS,  that each person whose  signature
appears below  constitutes and appoints Scott J. Solano and Lawrence J. Fassler,
and each or any one of them,  his true and  lawful  attorney-in-fact  and agent,
with full power of  substitution  and  resubstitution,  for him and in his name,
place  and  stead,  in any and all  capacities,  to sign any and all  amendments
(including  post-effective  amendments) to this Registration  Statement,  and to
file the same,  with all exhibits  thereto,  and other  documents in  connection
therewith,  with the  Securities  and Exchange  Commission,  granting  unto said
attorneys-in-fact  and agents,  and each of them, full power and authority to do
and perform each and every act and thing  requisite  and necessary to be done in
connection therewith,  as fully to all intents and purposes as he might or could
do in person,  hereby  ratifying and confirming all that said  attorneys-in-fact
and agents,  or any of them,  or their or his  substitutes  or  substitute,  may
lawfully do or cause to be done by virtue hereof.

<TABLE>
         Pursuant  to the  requirements  of the  Securities  Act of  1933,  this
Registration  Statement  has  been  signed  by  the  following  persons  in  the
capacities and on the dates indicated.

<CAPTION>
Signature                                        Title                                    Date


<S>                                   <C>                                         <C>
/s/ Scott J. Solano                   President, Chief Executive Officer          December 2, 1998
- ---------------------------------     and Director (Principal Executive
Scott J. Solano                       Officer)



/s/ John D. Miller                    Chief Financial Officer,                    December 2, 1998
- ---------------------------------     Treasurer and Director 
John D. Miller                        (Principal Financial and
                                      Accounting Officer)

/s/ Craig E. Dauchy                   Director                                    December 2, 1998
- ---------------------------------
Craig E. Dauchy



/s/ George B. Borkow                  Director                                    December 2, 1998
- ---------------------------------
George B. Borkow
</TABLE>



<PAGE>


                                    EXHIBITS


Exhibit
Number
- ------
5                 Opinion of Lawrence J. Fassler

23.1              Consent of Ernst & Young LLP, Independent Auditors

23.2              Consent of Lawrence J. Fassler (included in Exhibit 5)

24                Power of Attorney  (contained on the signature page)






[AVE logo}

                                                                       EXHIBIT 5



December 2, 1998



Arterial Vascular Engineering, Inc.
3576 Unocal Place
Santa Rosa, CA  95403


Ladies and Gentlemen:

I am General Counsel of Arterial Vascular Engineering,  Inc. (the "Company") and
am rendering this opinion with respect to certain matters in connection with the
filing by the Company of a Registration Statement on Form S-8 (the "Registration
Statement") with the Securities and Exchange Commission covering the offering of
up to 3,000,000  shares of the  Company's  Common Stock,  $.001 par value,  (the
"Shares") pursuant to its 1996 Equity Incentive Plan (the "Plan").

In connection with this opinion, I have examined the Registration  Statement and
related Prospectus,  the Company's  Certificate of Incorporation and By-laws, as
amended, and such other documents,  records,  certificates,  memoranda and other
instruments as I deem necessary as a basis for this opinion.  I have assumed the
genuineness and authenticity of all documents submitted to me as originals,  the
conformity to originals of all documents submitted to me as copies thereof,  and
the due execution and delivery of all documents where due execution and delivery
are a prerequisite to the effectiveness thereof.

On the basis of the foregoing, and in reliance thereon, I am of the opinion that
the Shares,  when sold and issued in accordance with the Plan, the  Registration
Statement  and related  Prospectus,  will be validly  issued,  fully  paid,  and
nonassessable  (except as to shares issued pursuant to certain  deferred payment
arrangements,  which will be fully  paid and  nonassessable  when such  deferred
payments are made in full).

I consent  to the  filing of this  opinion  as an  exhibit  to the  Registration
Statement.

Very truly yours,


/s/ Lawrence J. Fassler

Lawrence J. Fassler
General Counsel

ARTERIAL VASCULAR ENGINEERING, INC.                         E-Mail: www.avei.com
- --------------------------------------------------------------------------------
3576 UNOCAL PLACE                                            Tel: (707) 525-0111
SANTA ROSA, CALIFORNIA 95403                                 Fax: (707) 525-0114





                                                                    EXHIBIT 23.1


               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS



We consent to the  incorporation by reference in the  Registration  Statement on
Form S-8  pertaining  to the 1996 Equity  Incentive  Plan of  Arterial  Vascular
Engineering,  Inc.  of our  report  dated  July 17,  1998,  with  respect to the
consolidated financial statements and schedule of Arterial Vascular Engineering,
Inc. and  Subsidiaries  included in the Annual  Report on Form 10-K for the year
ended June 30, 1998, filed with the Securities and Exchange Commission.



                                                           /s/ ERNST & YOUNG LLP


Palo Alto, California
November 24, 1998




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission